Elanco Animal Health
NYSE: ELAN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-04-29
Elanco Animal Health (ELAN) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for ELAN.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
ELAN historical valuation range
Where current P/E sits in ELAN's own 5Y range.
ELAN intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
ELAN valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 2.31x
Is ELAN overvalued in 2026?
Elanco Animal Health (ELAN) currently trades at $21.80 per share with a market capitalization of $10,886,471,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 51/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
ELAN currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 2.3x, the market is valuing the company primarily on its revenue rather than its earnings.
Our discounted cash flow model estimates ELAN's intrinsic value at $31.06 per share, against the current market price of $21.80. This implies a margin of safety of +17.22%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: ELAN trades at a fair valuation on our framework, with a Smart Value Score of 51/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is ELAN overvalued in 2026?
Based on a Smart Value Score of 51/100, ELAN is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is ELAN's fair value?
Our DCF model estimates ELAN's intrinsic value at $31.06 per share, versus the current price of $21.80. This produces a margin of safety of +17.22%.
What P/E ratio does ELAN trade at?
ELAN does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.
Is ELAN a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 51/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does ELAN's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on ELAN.
What is ELAN's Smart Value Score?
ELAN's Smart Value Score is 51/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.